[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-213033-en":3,"doc-seo-213033-105":30,"detail-sidebar-cat-0-en-105":92},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":27,"seo_description":14,"update_tm":28,"read_time":29},213033,137451207643,"Margaret","https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2",8,"Research & Report","Overactive Bladder Syndrome in Women - Short-Term Benefits and Potential Harms of Therapeutic Modalities: A European Association of Urology Evidence Review","Overactive bladder syndrome (OAB) is highly prevalent in women and substantially affects quality of life. This evidence review synthesizes controlled trial data to determine the short-term effectiveness, safety, and potential harms of conservative, pharmacological, and surgical therapeutic modalities. Search and appraisal followed Medline, Embase, and Cochrane trial databases, with risk-of-bias evaluation and modified GRADE-based quality assessment. Antimuscarinics and beta-3 agonists improve outcomes versus placebo but differ in adverse-event profiles; onabotulinumtoxin-A shows benefits alongside increased AUR/CISC and UTIs. Second-line options such as sacral neuromodulation and PTNS are evaluated, with therapy choice guided by individual patient factors.","What are the short-term benefits and potential harms of therapeutic modalities for the management of overactive bladder syndrome in women? A review of evidence under the  \nauspices of the European Association of Urology, Female Non-Neurogenic LUTS Guidelines Panel  \nFawzy Faraga , Vasileios I. Sakalisb, Serenella Monagas Arteagac, Néha Sihrad, Markos Karavitakise, Salvador Arlandisf , Kari Bøg, Hanny Cobussen-Boekhorsth, Elisabetta Costantinii , Monica de Heidej, Jan Groenk , Benoit Peyronnetn, Veronique Phéo , Mary-Lynne van Poelgeest-Pomfretp, Tine W. L. vanden Bosj, Huub van der Vaartq, Christopher K. Hardingr*, Marie Carmela Lapitanl* , Muhammad Imran Omarm*, Arjun K. Nambiars*  \n*Senior authors  \na Department of Urology, Sohag University Hospital, Sohag, Egypt.  \nb Department of Urology, Agios Pavlos General Hospital of Thessaloniki, Thessaloniki, Greece.  \nc Department of Urology, University Hospital of San Agustín, Avilés, Spain.  \nd Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. e Department of Urology, Lefkos Stavros Clinic, Athens, Greece  \nf Urology Department, La Fe University and Polytechnic Hospital, Valencia, Spain.  \ng Department of Sports Medicine, Norwegian School of Sport Sciences, Oslo, Norway.  \nh Department of Urology, Radboud UMC, Nijmegen, The Netherlands.  \ni Department of Medicine and Surgery, University of Perugia, Perugia, Italy. j Bekkenbodem4All, Tiel, The Netherlands  \nk Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands.  \nl College of Medicine/Philippine General Hospital/National institutes of Health, University of the Philippines Manila, Manila, Philippines.  \nm University of Aberdeen, Aberdeen, UK; European Association of Urology, Arnhem, The Netherlands.  \nn Department of Urology, University of Rennes, Rennes, France.  \no Department of Urology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Academic Hospital, Sorbonne University, Paris, France.  \np World Federation of Incontinence and Pelvic Problems (WFIPP), Leiden, The Netherlands. q Department of Obstetrics and Gynecology, University Medical Center, Utrecht, The Netherlands.  \nr Department of Urology, Freeman Hospital, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK; Translational and Clinical Research Institute, Newcastle Universitys Department of Urology, Freeman Hospital, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK.  \nCorresponding author  \nMr. Arjun K. Nambiar Freeman Hospital Department of Urology Freeman Road  \nHigh Heaton  \nNE7 7DN Newcastle upon Tyne United Kingdom  \nArjun K Nambiar  \nKeywords  \nAnticholinergics, female lower urinary tract symptoms, onabotulinum toxin, overactive bladder , sacral neuromodulation, systematic review, urgency incontinence,  \nWord Count  \nAbstract – 291 Text – 4317  \nABSTRACT  \nContext  \nOveractive bladder syndrome (OAB) is highly prevalent among women and has negative impact on their quality of life. The current available treatments for OAB symptoms include conservative, pharmacological, or surgical modalities.  \nObjectives  \nTo provide an updated contemporary evidence document regarding OAB treatment options and determine the short-term effectiveness, safety, and potential harms of the available treatment modalities for women with OAB syndrome.  \nEvidence Acquisition and methods  \nThe Medline, Embase and Cochrane controlled trials databases and [clinicaltrial.gov](clinicaltrial.gov) were searched for all relevant publications up to May 2022. Risk of bias assessment followed the recommended tool in the Cochrane Handbook for Systematic Reviews of Interventions and quality of evidence was assessed using modified GRADE criteria. Meta-analysis was performed where appropriate.  \nEvidence Synthesis  \nAntimuscarinics and Beta-3 agonists were significantly more effective than placebo across most outcomes, with beta-3 agonists more effective at reducing nocturia episodes and antimuscarinics causing significantly higher adverse e","cbCaidGS7gOKhx02","https://ap.wps.com/l/cbCaidGS7gOKhx02","pdf",286087,1,30,"English","en",105,"# Context\n# Objectives\n# Evidence Acquisition and methods\n# Evidence Synthesis\n# Conclusions and Patient Summary\n# 1. Introduction","[{\"question\":\"What question does this review address about overactive bladder syndrome (OAB) in women?\",\"answer\":\"It evaluates the short-term effectiveness, safety, and potential harms of available treatment modalities for women with OAB syndrome.\"},{\"question\":\"Which treatments showed the greatest improvements compared with placebo?\",\"answer\":\"Antimuscarinics and beta-3 agonists were more effective than placebo across most outcomes; onabotulinumtoxin-A was also more effective than placebo across most outcomes.\"},{\"question\":\"What major harms or adverse events are highlighted for key therapies?\",\"answer\":\"Antimuscarinics caused significantly higher adverse events; onabotulinumtoxin-A had substantially higher rates of AUR/CISC and UTIs. Sacral neuromodulation showed different tolerability outcomes, including removal and revision rates and recurrent UTI differences compared with other options.\"}]","Overactive Bladder Syndrome in Women - Short-Term Benefits and Potential Harms of Therapeutic Modalities: A European Association of Urology Evidence Review | PDF",1788752589,76,{"code":4,"msg":31,"data":32},"ok",{"site_id":24,"language":23,"slug":33,"title":13,"keywords":34,"description":14,"schema_data":35,"social_meta":87,"head_meta":89,"extra_data":91,"updated_unix":28},"overactive-bladder-syndrome-in-women-short-term-benefits-and-potential-harms-of-therapeutic-modalities-a-european-association-of-urology-evidence-review","",{"@graph":36,"@context":86},[37,54,69],{"@type":38,"itemListElement":39},"BreadcrumbList",[40,44,48,51],{"item":41,"name":42,"@type":43,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":45,"name":46,"@type":43,"position":47},"https://docshare.wps.com/document/","Document",2,{"item":49,"name":12,"@type":43,"position":50},"https://docshare.wps.com/document/research-report/",3,{"item":52,"name":13,"@type":43,"position":53},"https://docshare.wps.com/document/overactive-bladder-syndrome-in-women-short-term-benefits-and-potential-harms-of-therapeutic-modalities-a-european-association-of-urology-evidence-review/213033/",4,{"url":52,"name":13,"@type":55,"author":56,"headline":13,"publisher":58,"fileFormat":61,"inLanguage":23,"description":14,"dateModified":62,"datePublished":63,"encodingFormat":61,"isAccessibleForFree":64,"interactionStatistic":65},"DigitalDocument",{"name":9,"@type":57},"Person",{"url":41,"name":59,"@type":60},"DocShare","Organization","application/pdf","2026-09-11","2026-09-07",true,{"@type":66,"interactionType":67,"userInteractionCount":20},"InteractionCounter",{"@type":68},"ViewAction",{"@type":70,"mainEntity":71},"FAQPage",[72,78,82],{"name":73,"@type":74,"acceptedAnswer":75},"What question does this review address about overactive bladder syndrome (OAB) in women?","Question",{"text":76,"@type":77},"It evaluates the short-term effectiveness, safety, and potential harms of available treatment modalities for women with OAB syndrome.","Answer",{"name":79,"@type":74,"acceptedAnswer":80},"Which treatments showed the greatest improvements compared with placebo?",{"text":81,"@type":77},"Antimuscarinics and beta-3 agonists were more effective than placebo across most outcomes; onabotulinumtoxin-A was also more effective than placebo across most outcomes.",{"name":83,"@type":74,"acceptedAnswer":84},"What major harms or adverse events are highlighted for key therapies?",{"text":85,"@type":77},"Antimuscarinics caused significantly higher adverse events; onabotulinumtoxin-A had substantially higher rates of AUR/CISC and UTIs. Sacral neuromodulation showed different tolerability outcomes, including removal and revision rates and recurrent UTI differences compared with other options.","https://schema.org",{"og:url":52,"og:type":88,"og:title":13,"og:site_name":59,"og:description":14},"article",{"robots":90,"canonical":52},"index,follow",{"doc_id":7,"site_id":24},{"code":4,"msg":5,"data":93},[94,98,102,106,111,116,121,123,128,131,135],{"id":20,"doc_module":4,"doc_module_name":46,"category_name":95,"show_sort_weight":96,"slug":97},"Story & Novel",90,"story-novel",{"id":47,"doc_module":4,"doc_module_name":46,"category_name":99,"show_sort_weight":100,"slug":101},"Literature",80,"literature",{"id":53,"doc_module":4,"doc_module_name":46,"category_name":103,"show_sort_weight":104,"slug":105},"Exam",70,"exam",{"id":107,"doc_module":4,"doc_module_name":46,"category_name":108,"show_sort_weight":109,"slug":110},5,"Comic",60,"comic",{"id":112,"doc_module":4,"doc_module_name":46,"category_name":113,"show_sort_weight":114,"slug":115},6,"Technology",50,"technology",{"id":117,"doc_module":4,"doc_module_name":46,"category_name":118,"show_sort_weight":119,"slug":120},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":46,"category_name":12,"show_sort_weight":21,"slug":122},"research-report",{"id":124,"doc_module":4,"doc_module_name":46,"category_name":125,"show_sort_weight":126,"slug":127},9,"Religion & Spirituality",20,"religion-spirituality",{"id":126,"doc_module":4,"doc_module_name":46,"category_name":129,"show_sort_weight":126,"slug":130},"World Cup","world-cup",{"id":132,"doc_module":4,"doc_module_name":46,"category_name":133,"show_sort_weight":132,"slug":134},10,"Lifestyle","lifestyle",{"id":136,"doc_module":4,"doc_module_name":46,"category_name":137,"show_sort_weight":107,"slug":138},19,"General","general"]